EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

EEDGAR/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice. EDGAR is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. EDGAR/calls is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search
Home›Stocks›TLSA

TLSA

Tiziana Life Sciences Ltd

Sell
$1.23
▲ +4.24%
$1.23▼ -22.15%
over 1Y
L $1.08EODHDH $2.50
Today+4.2%
1W+7.0%
1M-12.1%
3M-0.8%
YTD-23.1%
1Y-22.2%
OverviewValuationQualityFilings
Rating
Sell
Quality
F
Valuation
Fair value
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 7 analysts
Buy

Mixed signals in the latest filings.

Tiziana Life Sciences Ltd shows limited reported revenue.

On these fundamentals, TLSA screens as SELL on the SEC figures.

Financials · annual, by fiscal year

No income data filed.

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$157M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield—
FCF yield—

Quality & risk

ROIC (est.)—
Free cash flow—
Total debt—
Net cash—

Capital returns

Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+8.1%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Recent filings

all on EDGAR ↗
6-KPeriod ending 2026-06-252026-06-25open ↗4Period ending 2026-06-122026-06-17open ↗6-KPeriod ending 2026-06-152026-06-15open ↗6-KPeriod ending 2026-05-282026-05-28open ↗3Period ending 2026-03-182026-05-22open ↗6-KPeriod ending 2026-05-212026-05-21open ↗6-KPeriod ending 2026-05-192026-05-19open ↗6-KPeriod ending 2026-05-142026-05-14open ↗20-FPeriod ending 2025-12-312026-05-01open ↗NT 20-FPeriod ending 2025-12-312026-04-30open ↗6-KPeriod ending 2026-04-162026-04-16open ↗6-KPeriod ending 2026-04-142026-04-14open ↗

Quality score

F
ValueGrowthProfitHealthMom.
Value—
Growth—
Profitability—
Financial health—
MomentumF
1.0852-week2.50
Revenue
—
Net margin
—
ROE
—
P/E
—

SEC fundamentals

Frequently asked

Is Tiziana Life Sciences Ltd (TLSA) a buy?
TLSA currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Mixed signals in the latest filings.
What is Tiziana Life Sciences Ltd's quality score?
TLSA scores 31.631654332776314/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0001723069, latest 6-K filed 2026-06-25) · EODHD · as of 7/1/2026, 4:50:38 AM.

Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC
2026-06-12
CERRONE GABRIELE M
Director
Award15.0K @ $1.11$16.6K

Recent news

market news →
Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million MoreBullish
nasdaq.com· 2026-05-29
Tiziana Releases Positive Update For Intranasal Foralumab In Treating Multiple SclerosisBullish
nasdaq.com· 2026-05-20
Sector Update: Healthcare Stocks Gain Late Afternoon
finance.yahoo.com· 2026-05-19
Sector Update: Healthcare Stocks Rise Tuesday Afternoon
finance.yahoo.com· 2026-05-19
Tiziana says updated data for multiple sclerosis therapy shows long-term safetyBullish
seekingalpha.com· 2026-05-19
Dow, Nasdaq close lower as Treasury yields hit fresh highsBullish
finance.yahoo.com· 2026-05-19

Vs tracked universe

compare →

1192 tracked peers · median

EDGAR Score32 vs 67
Revenue growth— vs 7.5%
Net margin— vs 10.0%
Return on equity— vs 12.0%
P/E— vs 25.7

News sentiment

EODHD · 3d
Neutral
-0.01
vs typical · 6 articles
↑ improving

Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.